Merck to present new data in five tumor types from studies svaluating pembrolizumab, the company’s investigational anti-PD-1 antibody, at ESMO 2014
3 September 2014 | By Merck
Merck announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody...